Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeClinical Trials, Studies, Data Updates5-Yr Results Of The GORE® EXCLUDER® Iliac Branch Endoprosthesis Pivotal U.S. Multicenter Study Confirm Safety, Efficacy and Durability

5-Yr Results Of The GORE® EXCLUDER® Iliac Branch Endoprosthesis Pivotal U.S. Multicenter Study Confirm Safety, Efficacy and Durability

GORE® EXCLUDER®

 

W. L. Gore & Associates (Gore), today announced that five-year results of the U.S. prospective, multicenter study (N = 63) of endovascular repair of iliac aneurysms using the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE) were presented at the 2021 Society for Vascular Surgery Annual Meeting. Results of the study confirmed the safety, efficacy and durability of the IBE for treatment of aortoiliac and iliac artery aneurysms.

Approved by the U.S. Food & Drug Administration (FDA) in February 2016, the GORE EXCLUDER Iliac Branch Endoprosthesis was the first off-the-shelf aortic branch device approved in the U.S. and remains the only device indicated for the endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms.

Five-year primary patency of the internal iliac artery and external iliac artery IBE limbs was 95.1% and 100%, respectively. Furthermore, no patients experienced new onset buttock claudication on the IBE side or new onset erectile dysfunction. Additionally, there were no Type I or Type III endoleaks and no device migrations identified by the core lab, and freedom from secondary intervention was 88.2%. The device offers a treatment option that allows patients the benefits of endovascular therapy yet preserves pelvic perfusion.

“The positive outcomes from this five-year study validate the effectiveness and durability of the GORE EXCLUDER Iliac Branch Endoprosthesis for the treatment of iliac artery aneurysms,” said Darren B. Schneider, M.D., the study National Principal Investigator and Chief of Vascular Surgery and Endovascular Therapy at Penn Medicine and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. “Importantly, the IBE reduces the risk of common iliac artery enlargement and rupture while maintaining patency of the internal iliac artery to prevent complications associated with internal iliac artery sacrifice.”

Used in conjunction with the GORE® EXCLUDER AAA Endoprosthesis, the IBE isolates the common iliac artery from systemic blood flow and preserves blood flow in the external iliac and internal iliac arteries. Its design allows for a two-staged repositionable deployment for precise placement and has a pre-cannulated internal iliac gate and bi-femoral delivery for ease-of-use.

The GORE EXCLUDER Iliac Branch Endoprosthesis is part of the continually growing GORE EXCLUDER Device family and GORE® TAG® Devices that share a mission to effectively treat aortic aneurysms through minimally invasive means, backed by Gore’s highly rated clinical support team and comprehensive educational offerings.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy